Affiliation:
1. Keio University School of Medicine
2. University of Melbourne
3. Centre for Addiction and Mental Health
4. McGill University
5. Douglas Mental Health University Institute
Abstract
Abstract
Schizophrenia is associated with widespread cortical thinning and abnormality in the structural covariance network, which may reflect connectome alterations due to treatment effect or disease progression. Notably, patients with treatment-resistant schizophrenia (TRS) have stronger and more widespread cortical thinning, but it remains unclear whether structural covariance is associated with treatment response in schizophrenia. We therefore organized a multicenter magnetic resonance imaging study to assess structural covariance in a large population of TRS and non-TRS, who had been resistant and responsive to non-clozapine antipsychotics, respectively. Whole-brain structural covariance for cortical thickness was assessed in 102 patients with TRS, 77 patients with non-TRS, and 79 healthy controls (HC). Network based statistics were used to examine the difference in structural covariance networks among the three groups. Moreover, the relationship between altered individual differentiated structural covariance and clinico-demographics was also explored. Patients with non-TRS exhibited greater structural covariance compared to HC, mainly in the fronto-temporal and fronto-occipital regions, while there were no significant differences in structural covariance between TRS and non-TRS or HC. Higher individual differentiated structural covariance was associated with lower general scores of the Positive and Negative Syndrome Scale in the non-TRS group, but not in the TRS group. These findings suggest that reconfiguration of brain networks via coordinated cortical thinning is related to treatment response in schizophrenia. Further longitudinal studies are warranted to confirm if greater structural covariance could serve as a marker for treatment response in this disease.
Publisher
Research Square Platform LLC
Reference57 articles.
1. An evaluation of variation in published estimates of schizophrenia prevalence from 19902013: a systematic literature review;Simeone JC;BMC Psychiatry,2015
2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016;GBD 2016 Disease and Injury Incidence and Prevalence Collaborators;Lancet,2017
3. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016;Charlson FJ;Schizophr Bull,2018
4. Role of dopamine D(2) receptors for antipsychotic activity;Ginovart N;Handb Exp Pharmacol,2012
5. D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient;Kapur S;Biol Psychiatry,2001